COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Anhui warns after incorrect information in a form catches public attention
- Chinese milk tea chain fined $1.5 million for Louis Vuitton trademark infringement
- Exhibition recreating Japanese war criminals' trial opens in Harbin
- Sichuan hospital launches imaging training for Zambia's medical workforce
- Mainland reiterates support for Taiwan's agricultural exports
- 150-million-year-old fossil sheds light on bird tail evolution
